Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer

被引:9
作者
Bothwell, Katelyn D. [1 ,2 ]
Folaron, Margaret [1 ,3 ]
Seshadri, Mukund [1 ,3 ,4 ]
机构
[1] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA
[2] Univ New England, Coll Osteopath Med, Biddeford, ME 04005 USA
[3] Roswell Pk Canc Inst, Dept Mol & Cellular Biophys & Biochem, Buffalo, NY 14263 USA
[4] Roswell Pk Canc Inst, Dept Oral Med Head & Neck Surg, Buffalo, NY 14263 USA
关键词
head and neck squamous cell carcinomas; angiogenesis; vascular disrupting agents; bioluminescence imaging; magnetic resonance imaging; SQUAMOUS-CELL CARCINOMA; TARGETING AGENT; DYNAMIC BIOLUMINESCENCE; 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID; CHEMOTHERAPEUTIC EFFICACY; ANTITUMOR-ACTIVITY; COMBINATION; BEVACIZUMAB; THERAPY; ZD6126;
D O I
10.3390/cancers8010011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular disrupting agents (VDAs) represent a relatively distinct class of agents that target established blood vessels in tumors. In this study, we examined the preclinical activity of the second-generation VDA OXi4503 against human head and neck squamous cell carcinoma (HNSCC). Studies were performed in subcutaneous and orthotopic FaDu-luc HNSCC xenografts established in immunodeficient mice. In the subcutaneous model, bioluminescence imaging (BLI) along with tumor growth measurements was performed to assess tumor response to therapy. In mice bearing orthotopic tumors, a dual modality imaging approach based on BLI and magnetic resonance imaging (MRI) was utilized. Correlative histologic assessment of tumors was performed to validate imaging data. Dynamic BLI revealed a marked reduction in radiance within a few hours of OXi4503 administration compared to baseline levels. However, this reduction was transient with vascular recovery observed at 24 h post treatment. A single injection of OXi4503 (40 mg/kg) resulted in a significant (p < 0.01) tumor growth inhibition of subcutaneous FaDu-luc xenografts. MRI revealed a significant reduction (p < 0.05) in volume of orthotopic tumors at 10 days post two doses of OXi4503 treatment. Corresponding histologic (H&E) sections of Oxi4503 treated tumors showed extensive areas of necrosis and hemorrhaging compared to untreated controls. To the best of our knowledge, this is the first report, on the activity of Oxi4503 against HNSCC. These results demonstrate the potential of tumor-VDAs in head and neck cancer. Further examination of the antivascular and antitumor activity of Oxi4503 against HNSCC alone and in combination with chemotherapy and radiation is warranted.
引用
收藏
页数:12
相关论文
共 44 条
[1]   Comparison of Optical and Power Doppler Ultrasound Imaging for Non-Invasive Evaluation of Arsenic Trioxide as a Vascular Disrupting Agent in Tumors [J].
Alhasan, Mustafa K. ;
Liu, Li ;
Lewis, Matthew A. ;
Magnusson, Jennifer ;
Mason, Ralph P. .
PLOS ONE, 2012, 7 (09)
[2]  
[Anonymous], P ASCO ANN M CHIC IL
[3]   Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck [J].
Argiris, A. ;
Kotsakis, A. P. ;
Hoang, T. ;
Worden, F. P. ;
Savvides, P. ;
Gibson, M. K. ;
Gyanchandani, R. ;
Blumenschein, G. R., Jr. ;
Chen, H. X. ;
Grandis, J. R. ;
Harari, P. M. ;
Kies, M. S. ;
Kim, S. .
ANNALS OF ONCOLOGY, 2013, 24 (01) :220-225
[4]   Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors [J].
Bahleda, Rastislav ;
Sessa, Cristiana ;
Del Conte, Gianluca ;
Gianni, Luca ;
Capri, Giuseppe ;
Varga, Andrea ;
Oprea, Corina ;
Daglish, Byzance ;
Hospitel, Marie ;
Soria, Jean-Charles .
INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) :1188-1196
[5]   Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent [J].
Benezra, M. ;
Phillips, E. ;
Tilki, D. ;
Ding, B-S ;
Butler, J. ;
Dobrenkov, K. ;
Siim, B. ;
Chaplin, D. ;
Rafii, S. ;
Rabbany, S. ;
Bradbury, M. S. .
LEUKEMIA, 2012, 26 (08) :1771-1778
[6]   Chemoradiation after surgery for high-risk head and neck cancer patients: How strong is the evidence? [J].
Bernier, J ;
Cooper, JS .
ONCOLOGIST, 2005, 10 (03) :215-224
[7]   Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model [J].
Bozec, A. ;
Sudaka, A. ;
Fischel, J-L ;
Brunstein, M-C ;
Etienne-Grimaldi, M-C ;
Milano, G. .
BRITISH JOURNAL OF CANCER, 2008, 99 (01) :93-99
[8]  
Chan LS, 2007, ANTICANCER RES, V27, P2317
[9]   Combination of vascular disrupting agents and ionizing radiation [J].
Clemenson, Celine ;
Chargari, Cyrus ;
Deutsch, Eric .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 86 (02) :143-160
[10]   The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models [J].
Clemenson, Celine ;
Jouannot, Erwan ;
Merino-Trigo, Ana ;
Rubin-Carrez, Chantal ;
Deutsch, Eric .
INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) :273-284